欢迎访问《现代生物医学进展》编辑部！

目的：比较阿德福韦酯与拉米夫定治疗慢性乙肝的远期疗效。方法：回顾性分析2012 年5 月至2014 年5 月我院收治的80 例慢性乙肝患者的临床资料，随机分为研究组和对照组，每组各40 例。研究组患者给予阿德福韦酯治疗，对照组患者给予拉米夫定治疗。观察两组患者不同时段肝功能指标复常率、病毒量转阴率、乙肝E 抗原（HBeAg）转阴率、粒细胞降低率及乙肝病毒脱氧核糖核酸（HBV-DNA）抑制率，并比较两组患者不良反应发生率。结果：研究组患者肝功能指标复常率、血病毒量转阴率、HbeAg 转阴率均显著高于对照组同期对应值，差异具有统计学意义（P<0.05），但两组患者血粒细胞降低率无显著差异（P>0.05）；研究组患者HBV-DNA水平总抑制率高于对照组，差异有统计学意义（P<0.05）；两组患者均无严重不良反应发生（P>0.05）。结论：阿德福韦酯治疗慢性乙肝的疗效更显著，能有效抑制HBV-DNA复制且安全性较高。

英文摘要:

Objective:To compare the curative effect of lamivudine and adefovir on the treatment of chronic hepatitis B.Methods:A retrospective analysis was conducted on the clinical data of 80 cases with chronic hepatitis B who were treated in our hospital from May 2012 to 2014, and the patients were randomly divided into the study group and the control group with 40 cases in each group. The patients in the study group were treated with adefovir, while the patients in the control group were treated with lamivudine. Then the recovery rate of liver function, negative rate of viral burden and HBeAg, the reduction rate of granulocyte and the incidence of adverse reactions of patients in the two groups were observed and compared.Results:The recovery rate of liver function, negative rate of viral burden and HBeAg of patients in the study group were higher than those of the patients in the control group with statistically significant differences (P<0.05), while there was no significant difference about the reduction rate of granulocyte between the two groups (P>0.05); The inhibition of HBV-DNA of patients in the study group was higher than that of the control group with statistically significant differences (P<0.05); There was no statistically significant difference about the adverse reactions between the two groups (P>0.05).Conclusion:It is indicated that the clinical effects of adefovir should be better on treatment of chronic hepatitis B with obvious efficacy and high safety.

View Full Text View/Add Comment Download reader